The Army’s New Vaccine Could Help Poor Countries End COVID-19
Joe Biden's refusal to lift COVID-19 vaccine intellectual property restrictions has protected Big Pharma profits and worsened the pandemic. But a new army-developed vaccine isn't covered by such restrictions — making it easily shareable with the entire world.

US president Joe Biden gives remarks on his administration’s response to the surge in COVID-19 cases. (Anna Moneymaker / Getty Images)
Progressive lawmakers are calling on President Joe Biden to take advantage of the fact that the US Army’s new pan-coronavirus vaccine recipe is not subject to intellectual property restrictions and share the information with the world.
According to the army, early research shows that the spike ferritin nanoparticle (SpFN) vaccine, developed by scientists at the Walter Reed Army Institute of Research, can “provide broad protection” against COVID-19 and future variants. The SpFN vaccine must still undergo Phase 2 and 3 of human trials, but if it proves successful, distributing the new vaccine around the globe could be a game-changer in the fight against the COVID pandemic.
While the vaccines that are widely available in the United States have proven safe and effective at preventing hospitalizations and death — even against new variants — manufacturers like Moderna and Pfizer have put profits first, prioritizing sales to wealthy countries while vigorously opposing efforts to allow poorer countries to manufacture their own versions of the vaccines. Meanwhile, COVID variants like Delta and Omicron have emerged and wreaked havoc across the globe.